Joan W. Miller
VANCOUVER, British Columbia — Much like the development of anti-VEGF was transformational in the treatment of age-related macular degeneration, the future identification of key pathways, potential therapeutic targets in those pathways and a better understanding of the disease could have a similar effect on treatment, Joan W. Miller, MD, said in the Pyron Award lecture at the American Society of Retina Specialists annual meeting.
Miller discussed the need for developing new therapies for early and intermediate age-related macular degeneration (AMD).
“In order to develop
Uncategorized